---
title: "Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296510282.md"
description: "Wedbush analyst Robert Driscoll maintained a Buy rating on IDEAYA Biosciences (IDYA) with a $60 price target. Driscoll, a 5-star analyst in the Healthcare sector, also covers Replimune Group and Kura Oncology. Additionally, Mizuho Securities issued a Buy rating for IDYA with a $50 price target."
datetime: "2026-08-20T14:55:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296510282.md)
  - [en](https://longbridge.com/en/news/296510282.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296510282.md)
generator: "portal-rs"
---

# Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)

In a report released today, Robert Driscoll from Wedbush maintained a Buy rating on IDEAYA Biosciences, with a price target of $60.00.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Driscoll is a 5-star analyst with an average return of 12.6% and a 47.47% success rate. Driscoll covers the Healthcare sector, focusing on stocks such as Replimune Group, Kura Oncology, and IDEAYA Biosciences.

In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $50.00 price target.

### Related Stocks

- [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md)
- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)
- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)

## Related News & Research

- [IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences | IDYA Stock News](https://longbridge.com/en/news/297635689.md)
- [IDEAYA targets year-end 2026 start for Phase 3 IDE849 trial in extensive-stage small cell lung cancer](https://longbridge.com/en/news/297497016.md)
- [Intellia Therapeutics to present at Morgan Stanley Global Healthcare Conference](https://longbridge.com/en/news/298034989.md)
- [Braveheart Bio, Inc.'s Quiet Period To Expire  on September 15th (NASDAQ:BRVE)](https://longbridge.com/en/news/298264807.md)
- [TPG’s Asia OneHealthcare said to confidentially file for US$2.5 billion IPO](https://longbridge.com/en/news/297874967.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**